Cargando…
Prevalence and covid 19 vaccination rate in a population of patients with schizophrenia and a substance use disorder
INTRODUCTION: As of August 27th, 2021, the diagnosed cases of COVID 19 in Spain are 4 758 003 with a prevalence of 10.03%. 68.4% of the Spanish population is fully vaccinated OBJECTIVES: Primary: To compare the prevalence of COVID infection in a cohort of patients with schizophrenia to patients with...
Autores principales: | Romero Guillena, S.L., De Burgos Berdud, I., Gálvez Medina, R., Serrano Rodriguez, E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565178/ http://dx.doi.org/10.1192/j.eurpsy.2022.685 |
Ejemplares similares
-
Comparison of prevalence, clinical evolution, and vaccination rate against covid 19 in a population of patients diagnosed with dual depression and non-dual depression
por: Romero Guillena, S.L., et al.
Publicado: (2022) -
Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen
por: Romero Guillena, S.L., et al.
Publicado: (2022) -
PALIPERIDONE PALMITATE 6-MONTH FORMULATION FOR THE TREATMENT OF SCHIZOPHRENIA: A 4-MONTH FOLLOW-UP STUDY
por: Romero Guillena, S. L., et al.
Publicado: (2023) -
Alternative initiation regimen of paliperidone palmitate long-acting injectable
por: Menendez Gil, I.E., et al.
Publicado: (2022) -
Effectiveness of antipsychotics in schizophrenia with comorbid substance use disorder
por: Lähteenvuo, M., et al.
Publicado: (2021)